TITLE

Drug ban threatens obesity control

PUB. DATE
December 1997
SOURCE
USA Today Magazine;Dec97, Vol. 126 Issue 2631, p7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports that controversy over weight-reduction drugs could threaten future efforts to develop and prescribe medications for obesity. The withdrawl of two obesity drugs fenfluramine and dexfenfluramine from the market in 1997; Reasons they were removed from the market; Number of people who die annually from obesity-related causes.
ACCESSION #
9712100525

 

Related Articles

  • After fen-phen. Cowley, Geoffrey; Springen, Karen // Newsweek;9/29/1997, Vol. 130 Issue 13, p46 

    Discusses the recall of the anti-obesity drugs fenfluramine (Pondimin) and dexfenfluramine (Redux). Inconclusive evidence of damage to heart valves in users of the drugs; Cost to American Home Products, the conglomerate that makes Pondimin and distributes Redux, of the recall; Pondimin's...

  • Redux: The cookie crumbles. Griffin, Katherine; Mason, Michael // Health (Time Inc. Health);Apr97, Vol. 11 Issue 3, p32 

    Focuses on the effectiveness of Redux, an appetite depressant drug. David Levitsky, an obesity specialist at Cornell University's studies that tested the effectiveness of fenfluramine, the active ingredient in Redux; Side effects of taking large doses of fenfluramine.

  • Who's to blame for Redux and fenfluramine? Golden, Frederic; Dowell, William // Time International (South Pacific Edition);09/29/97, Issue 39, p56 

    Attempts to assign blame for deadly diet pills such as Redux and fenfluramine. How the recall of the drugs could turn into one of the biggest medical-liability cases in history; The liability as being taken out against Wyeth-Ayerst Laboratories, a subsidiary of American Home Productions , which...

  • Who's to blame for Redux and fenfluramine? Golden, Frederic; Dowell, William // Time;9/29/1997, Vol. 150 Issue 13, p78 

    Attempts to assign blame for deadly diet pills such as Redux and fenfluramine. How the recall of the drugs could turn into one of the biggest medical-liability cases in history; The liability as being taken out against Wyeth-Ayerst Laboratories, a subsidiary of American Home Productions, which...

  • Interim recommendations issued for patients exposed to fenfluramine and dexfenfluramine.  // JAMA: Journal of the American Medical Association;12/03/97, Vol. 278 Issue 21, p1728 

    Discusses interim recommendations from the US Food and Drug Administration and other agencies for patients exposed to two appetite suppressant drugs, fenfluramine and dexfenfluramine. Withdrawal of the drugs, marketed under the trade names Pondimin and Redux, due to large number of patients who...

  • LETTER TO THE EDITOR. Mikhailidis, Dimitri P.; Jagroop, I. Anita // Angiology;Mar/Apr2002, Vol. 53 Issue 2, p243 

    Comments on the symptomatic calf pain associated with the use of fenfluramine. Observation of a shortening of the prothrombin time; Discussion of the mechanisms that mediated the phenomena; Effects of dexfenfluramine and fenfluramine on the platelet function.

  • Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of..  // JAMA: Journal of the American Medical Association;12/03/97, Vol. 278 Issue 21, p1729 

    Discusses cases of valvular heart disease in women treated with two appetite suppressants, fenfluramine and dexfenfluramine. Summary of date used by the US Food and Drug Administration in its decision to request voluntary withdrawal of these drugs from the market; Interim public health...

  • Dexfenfluramine/fenfluramine.  // Reactions Weekly;6/9/2007, Issue 1155, p9 

    The article presents the case of a woman who was found to have valvular heart disorders 7 years after the cessation of intermittent treatment involving dexfenfluramine and fenfluramine. The patient who had a history of anorexia nervosa after her first pregnancy also underwent double valve...

  • Adverse reactions to dexfenfluramine. Ernsberger, Paul // Healthy Weight Journal;Jan/Feb97, Vol. 11 Issue 1, p13 

    Looks at the various side effects of dexfenfluramine. Includes primary pulmonary hypertension; Brain damage; Possible chromosome damage; Acute glaucoma and pancreatitis as other side effects; Drug interaction with phentermine; Withdrawal symptoms.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics